Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Capital Leases (2022 - 2024)

Inhibikase Therapeutics (IKT) has disclosed Capital Leases for 3 consecutive years, with $58330.0 as the latest value for Q1 2024.

  • Quarterly Capital Leases fell 67.25% to $58330.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $58330.0 through Mar 2024, down 67.25% year-over-year, with the annual reading at $90124.0 for FY2023, 56.13% down from the prior year.
  • Capital Leases for Q1 2024 was $58330.0 at Inhibikase Therapeutics, down from $90124.0 in the prior quarter.
  • The five-year high for Capital Leases was $232020.0 in Q3 2022, with the low at $58330.0 in Q1 2024.
  • Average Capital Leases over 3 years is $147859.9, with a median of $149971.0 recorded in 2023.
  • The sharpest move saw Capital Leases tumbled 47.84% in 2023, then crashed 67.25% in 2024.
  • Over 3 years, Capital Leases stood at $205451.0 in 2022, then plummeted by 56.13% to $90124.0 in 2023, then crashed by 35.28% to $58330.0 in 2024.
  • According to Business Quant data, Capital Leases over the past three periods came in at $58330.0, $90124.0, and $121013.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.